The estimated Net Worth of Robert J Coury is at least $53.2 million dollars as of 2 March 2023. Mr Coury owns over 236,709 units of Viatris stock worth over $13,345,320 and over the last 10 years he sold VTRS stock worth over $23,279,020. In addition, he makes $16,605,440 as Exec. Chairman at Viatris.
Mr has made over 11 trades of the Viatris stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 236,709 units of VTRS stock worth $2,684,280 on 2 March 2023.
The largest trade he's ever made was exercising 750,000 units of Viatris stock on 24 June 2019 worth over $8,505,000. On average, Mr trades about 123,047 units every 123 days since 2015. As of 2 March 2023 he still owns at least 1,176,836 units of Viatris stock.
You can see the complete history of Mr Coury stock trades at the bottom of the page.
Robert J. Coury is the Exec. Chairman at Viatris.
As the Exec. Chairman of Viatris, the total compensation of Mr Coury at Viatris is $16,605,440. There are no executives at Viatris getting paid more.
Mr Coury is 60, he's been the Exec. Chairman of Viatris since . There are no older and 11 younger executives at Viatris.
Robert's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.
Over the last 4 years, insiders at Viatris have traded over $17,988,707 worth of Viatris stock and bought 85,788 units worth $1,086,462 . The most active insiders traders include Ian C Read, James M Kilts et Robert J Coury. On average, Viatris executives and independent directors trade stock every 13 days with the average trade being worth of $708,761. The most recent stock trade was executed by Rajiv Malik on 28 August 2024, trading 100,000 units of VTRS stock currently worth $1,195,000.
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
Viatris executives and other stock owners filed with the SEC include: